ASND
Ascendis Pharma A/S - USData as of 2026 Q2 (06-30) · 13F snapshot
Summary
Ascendis Pharma A/S - US (ASND) is held as common stock by 4 tracked hedge-fund managers, with a combined reported value of ~$144.27M; the largest are Izzy Englander, Ken Griffin, Renaissance Technologies. 3 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 4 new. 17 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Heating up
Common-stock holders43 also report options
Congress trades17
Price$230.05vs quarter-end-13.75%
Sectors0
This quarter's moves
Top holderNew4
Added0
Trimmed / sold0
Izzy EnglanderCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
| Investor | Value | % of portfolio | Action |
|---|
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $46.89M— of portfolio175,8002026 Q2
Value $24.83M— of portfolio93,1002026 Q2
Value $16.19M— of portfolio60,7002026 Q2
Value $5.33M— of portfolio20,0002026 Q2
Value $346.7K— of portfolio1,3002026 Q2
Value $213.4K— of portfolio8002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $46.89M | — | — |
| Ken GriffinPUT | $24.83M | — | — |
| Izzy EnglanderCALL | $16.19M | — | — |
| Paul Tudor JonesPUT | $5.33M | — | — |
| Izzy EnglanderPUT | $346.7K | — | — |
| Paul Tudor JonesCALL | $213.4K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.